Stocks should be crushed by global turmoil, Jim Cramer says. Instead, they're doing fine.
VIDEO ON MSN MONEY
The medical device company tackles spinal cord injury with multiple technologies.
By Tom Bishop, BI Research
The financial impact of spinal cord injury (SCI) is staggering, estimated at between $244,000 and $829,000 in the first year alone. Over a lifetime the costs could add up to $1 to $4 million.
The irony surrounding the Atlanta skyscraper is pretty tall, even if the company doesn't own it.
News came out recently that the company that owns the office building is struggling to meet its debt service as offices remain empty and the real estate crash continues to take a toll.
With stricter environmental regulations in the U.S. and signs of a slowdown in China, coal's importance to freight carriers will likely decline.
While coal production and demand are likely to grow over the next few years, driving traffic volume for freight carriers such as CSX Corporation (CSX) and Union Pacific (UNP), there may be a long-term shift away from this reliance.
Bullish chart patterns and relative performance analysis make these stocks worth buying on dips.
By Tom Aspray, MoneyShow.com
As noted on Friday, the daily analysis of the PowerShares QQQ Trust (QQQ) shows that it has now started to outperform the S&P 500.
In my weekly Starc band analysis of the Nasdaq 100 stocks, I wanted to concentrate not only on those that were the closest to their weekly Starc+ or Starc- bands, but also on how these stocks had performed against the major averages since October.
New models from Ford and GM won't affect investors' views. The market cares only about sales.
We got news of new cars galore Monday. We heared about midsize cars from the Big Three that could challenge the Japanese, cars with technology that appeals to youths, cars that show off U.S. craftsmanship in a way that makes the Japanese seem, well, equal to -- not better than -- Ford (F), GM (GM) or Chrysler.
If only it mattered to the stocks. First, we don't care about Chrysler unless we are trying to buy one. The idea of buying a European car company because of a strong Chrysler showing is pretty fanciful. Fiat is good. So what?
Even after a huge rally in 2011, this stock still has a full tank of gas.
By Nathan Slaughter, Energy & Income
Golar LNG (GLNG) shareholders will have fond memories of 2011 -- the stock delivered an impressive 196% return for the year. But the rally isn't over yet, because the same tailwinds behind it will continue blowing through at least 2014.
These stocks are in the sweet spot for continuing their winning ways into this year and beyond.
By Richard Moroney, Upside
Special to MoneyShow.com
Cascade (CASC): The leading maker of material handling equipment in North America, this company is highly leveraged to demand for forklifts. Its primary end markets include pulp and paper, grocery products, textiles, and consumer goods. Cascade has rallied 12% since announcing impressive October quarter results on Dec. 1.
Per-share earnings were $1.74, up from 79 cents and handily above the consensus of $1.20. Results reflect lower interest expense, a favorable tax rate, and improved gross profit margins. Total revenue increased 29% to $138 million and beat the consensus by $5 million. Sales have topped expectations in five of the last six quarters.
The payoff for CEO Reed Hastings' international push may take a long time.
For example, business leaders in the U.K. expect the country's economy to get worse in 2012, according to a poll released Monday. A recent Goldman Sachs survey forecast that the U.K.'s gross domestic product (GDP) will rise 0.7% this year, down from 0.9% in 2011.
The retailer sends mixed signals regarding the future of the e-reader.
What on earth is Barnes & Noble (BKS) doing pondering the spin-off of the division that makes its Nook e-readers and tablets? It’s hard to find a way to "spin" that news into anything resembling an upbeat signal for either Barnes & Noble or its stock.
William Lynch, the bookseller’s CEO, dropped the possibility of a spin-off into a discussion of the company’s prospects last week, even as he revealed that year-end results are likely to fall short of investors’ hopes and analysts’ forecasts.
Pipelines and processing plants put this MLP in the sweet spot as US gas production ramps up.
By Amy Calistri, The Daily Paycheck
Enterprise Products Partners LP (EPD), a Houston-based master limited partnership (MLP), operates over 50,000 miles of gas, crude oil, natural gas liquids (NGL) and petrochemical pipelines.
Travelers is upgraded to 'conviction buy' at Goldman, while Akamai is downgraded to 'sell' at Citigroup.
Monday's noteworthy upgrades include:
- Broadcom (BRCM) upgraded to Buy from Hold at Deutsche Bank
- Comcast (CMCSA) upgraded to Outperform from Neutral at Macquarie
- Hartford Financial (HIG) upgraded to Buy from Neutral at Goldman
- MetLife (MET) upgraded to Buy from Neutral at Goldman
- Travelers (TRV) upgraded to Conviction Buy from Buy at Goldman
- Akamai (AKAM) upgraded to Hold from Underperform at Jefferies
- J.C. Penney (JCP) upgraded to Hold from Sell at Deutsche Bank
The company's generics business is poised to grow after it recorded revenue of nearly $10 billion in 2010.
Biopharmaceutical includes primary care, specialty care, established products, emerging markets and oncology units that focus on treatment and prevention of cardiovascular and metabolic diseases, central nervous system disorders, arthritis and pain, respiratory diseases, urogenital conditions, cancer, eye disease and endocrine disorders, among others. Its diversified unit includes animal health, consumer health and nutritional products such as nutritional supplements and toddler formula products.
Booming foreign interest in domestic reserves creates big opportunity.
The U.S. and Canada are sitting on one of the biggest energy booms ever. An oil and gas production renaissance is under way, thanks to improved hydraulic fracturing and advances in drilling techniques. Though not without controversy, shale formations like the Marcellus, Utica and Eagle Ford have become hotbeds of North American drilling activity because these advances have made it possible to extract the plethora of fossil fuels trapped between the rocks.
With billions of dollars in revenue at stake, these regions have witnessed a land grab not seen since the California Gold Rush of the 1800s. While the usual suspects like Exxon (XOM) are staking their claims, North America's shale interests are getting plenty of attention from overseas sources as well.
Positive action on new drugs by FDA in 2011 bodes well for biopharmaceuticals in 2012, and Celgene can offer long-term growth.
"We see the FDA's modestly raised fiscal 2012 budget supporting continued improvement in the approval of new drugs on first review cycle," says Steven Silver, a biotech analyst at Standard & Poor's. The FDA's approval of new drugs in 2011 jumped 63% after an increase of about 50% in 2010, indicating a much-improved dedication by the FDA in supporting biotech and pharmaceutical companies in their quest for badly needed new drugs, Silver argues.
A recently launched oil and gas trust offers protected payouts and attractive yield.
By Elliott Gue, The Energy Strategist
Chesapeake Granite Wash Trust (CHKR), the newest addition to the universe of U.S. oil and gas trusts, went public on Nov. 11. It is also among the most promising and fastest-growing trusts in my coverage universe.
MORE ON MSN MONEY
Copyright © 2014 Microsoft. All rights reserved.
The idea of US crude being a shelter from turmoil abroad may not be as far fetched as it seems.
Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.
Contributors include professional investors and journalists affiliated with MSN Money.
Follow us on Twitter @topstocksmsn.
[BRIEFING.COM] The stock market capped the trading week with losses across the major averages. The S&P 500 fell 0.5% to surrender its weekly gain, while the Dow Jones Industrial Average (-0.7%) and Russell 2000 (-0.9%) underperformed. The two indices posted respective losses of 0.8% and 0.6% for the week.
Equity indices were pressured from the get-go after several heavyweights disappointed the market with their earnings and/or guidance, which led to some broader profit-taking. After ... More
More Market News
|There’s a problem getting this information right now. Please try again later.|